<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2012//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_120101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10822537</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>07</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>07</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2008</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1523-7060</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Jul</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Organic letters</Title>
                <ISOAbbreviation>Org. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Enantioselective synthesis of saframycin A and evaluation of antitumor activity relative to ecteinascidin/saframycin hybrids.</ArticleTitle>
            <Pagination>
                <MedlinePgn>75-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>[formula: see text] A short synthesis of saframycin A is described which begins with a readily available intermediate previously utilized for the total synthesis of ecteinascidin 743. A key step in this synthesis is the use of 1-fluoro-3,5-dichloropyridinium triflate to oxidize a phenolic ring to a 1,4-benzoquinone unit while simultaneously cleaving a methoxymethyl ether of a different phenolic ring to the corresponding phenol (4--&gt;5). The common intermediate (2) for the synthesis of saframycin A (1) and ecteinascidin 743 also allowed the synthesis of two hybrids of these structures (6 and 7). Whole cell bioassays for antitumor activity using lung, colon, melanoma, and prostate-derived tumor cell lines allowed a clear correlation of structure with biological activity in this series.</AbstractText>
            </Abstract>
            <Affiliation>Harvard University, Department of Chemistry and Chemical Biology, Cambridge, Massachusetts 02138, USA.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Martinez</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corey</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Org Lett</MedlineTA>
            <NlmUniqueID>100890393</NlmUniqueID>
            <ISSNLinking>1523-7052</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antibiotics, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antineoplastic Agents, Alkylating</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Dioxoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Isoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Tetrahydroisoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>114899-77-3</RegistryNumber>
                <NameOfSubstance>trabectedin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>66082-27-7</RegistryNumber>
                <NameOfSubstance>saframycin A</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antineoplastic Agents, Alkylating</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dioxoles</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Isoquinolines</DescriptorName>
                <QualifierName MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Stereoisomerism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tetrahydroisoquinolines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>5</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>7</Month>
                <Day>15</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>5</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10822537</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
